For children with relapsed or treatment-resistant blood cancers, CAR-T-cell therapy is creating new possibilities when conventional treatments are no longer enough. At Sheba Medical Center’s Edmond and Lily Safra Children’s Hospital, Ramat Gan (Tel Aviv District), Israel, advanced immunotherapy is combined with multidisciplinary pediatric expertise, family-centered support, education, and rehabilitation to help children return not only to health, but also to childhood. A diagnosis of childhood cancer changes life overnight, not only for the child, but for parents, siblings, and the entire family. When standard treatments no longer provide the desired response, families are often faced with difficult decisions while searching for additional options.

For many families in Ukraine, these decisions have become even more challenging. Ongoing disruption to healthcare services, the need to travel for highly specialized treatment, and the emotional burden of leaving home during an already overwhelming time have added further complexity to an already difficult journey.

For children with certain relapsed or refractory blood cancers, CAR-T-cell therapy has become an important treatment option. Rather than relying solely on chemotherapy, CAR-T-cell therapy uses the patient’s own immune cells, genetically reprogrammed to recognize and attack cancer cells.

At Sheba Medical Center in Israel, recognized by Newsweek among the World’s Best Hospitals and ranked among the world’s leading oncology hospitals, this innovative therapy is delivered within a comprehensive pediatric cancer program designed around the needs of children and their families.